Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Parexel buys software firm for $72m

Parexel International Corp., a Waltham biotechnology services company, said Thursday that it has purchased the software maker Liquent Inc. for $72 million.

Liquent, based in Horsham, Pa., makes software used by drug companies to manage regulatory submissions and product registrations. The purchase of Liquent will allow Parexel to expand the consulting services it provides to biotech and medical device companies.

Continue reading below

Liquent has more than 200 clients worldwide that use its software. Prior to the sale, Liquent was owned by the private equity firm Marlin Equity Partners, of Hermosa Beach, Calif.

With the addition of Liquent, Parexel increased its revenue projection for the 2013 fiscal year from between $1.63 billion and $1.66 billion to between $1.675 billion and $1.695 billion.

Parexel helps biotech companies with the drug-development and launch processes, and helps to maximize sales after­ drugs become available. The company employs about 14,000 people in 51 countries.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week